Ro 5-3335 is a benzodiazepine compound that functions as a core-binding factor (CBF) leukemia inhibitor; it inhibits the RUNX1–CBFβ protein–protein interaction and suppresses RUNX1/CBFB-dependent transactivation; exhibits antiproliferative activity against human CBF leukemia cell lines (IC50 = 1.1 μM, 21.7 μM, and 17.3 μM for ME-1, Kasumi-1, and REH cells, respectively); inhibits definitive hematopoiesis in zebrafish embryos; rescues preleukemic phenotype in RUNX1-ETO transgenic zebrafish; reduces leukemia burden in a mouse CBFB-MYH11 leukemia model upon oral administration (300 mg/kg/day for 30 days), as evidenced by decreased c-kit+ cells and reduced leukemic cell infiltration in liver, bone marrow, and spleen.